Terms: = Ovarian cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS
62 results:
1. Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.
Pernar Kovač M; Tadić V; Kralj J; Duran GE; Stefanelli A; Stupin Polančec D; Dabelić S; Bačić N; Tomicic MT; Heffeter P; Sikic BI; Brozovic A
Cell Mol Life Sci; 2023 Sep; 80(10):294. PubMed ID: 37718345
[TBL] [Abstract] [Full Text] [Related]
2. MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype.
Pernar Kovač M; Tadić V; Kralj J; Milković Periša M; Orešković S; Babić I; Banović V; Zhang W; Culig Z; Brozovic A
Biomed Pharmacother; 2023 Oct; 166():115349. PubMed ID: 37634476
[TBL] [Abstract] [Full Text] [Related]
3. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
[TBL] [Abstract] [Full Text] [Related]
4. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
Hada T; Miyamoto M; Ohtsuka Y; Suminokura J; Ito T; Kishimoto N; Nishitani S; Takada M; Imauji A; Tanabe R; Takano M
Diagn Pathol; 2023 Apr; 18(1):49. PubMed ID: 37081552
[TBL] [Abstract] [Full Text] [Related]
5. Mesonephric-like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas.
Mirkovic J; Olkhov-Mitsel E; Amemiya Y; Al-Hussaini M; Nofech-Mozes S; Djordjevic B; Kupets R; Seth A; McCluggage WG
Histopathology; 2023 Jun; 82(7):978-990. PubMed ID: 36860193
[TBL] [Abstract] [Full Text] [Related]
6. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract] [Full Text] [Related]
7. Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
Kralj J; Pernar Kovač M; Dabelić S; Polančec DS; Wachtmeister T; Köhrer K; Brozovic A
Br J Cancer; 2023 Mar; 128(7):1344-1359. PubMed ID: 36717670
[TBL] [Abstract] [Full Text] [Related]
8. Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in ovarian cancer and Reduce Acute Toxicity of Chemo-Drugs.
Tang H; Xie Y; Zhu M; Jia J; Liu R; Shen Y; Zheng Y; Guo X; Miao D; Pei J
Int J Nanomedicine; 2022; 17():3013-3041. PubMed ID: 35836838
[TBL] [Abstract] [Full Text] [Related]
9. In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2.
du Manoir S; Delpech H; Orsetti B; Jacot W; Pirot N; Noel J; Colombo PE; Sardet C; Theillet C
J Pathol; 2022 Jul; 257(3):367-378. PubMed ID: 35302657
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/cbp HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract] [Full Text] [Related]
11. GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p.
Li Y; Zhai Y; Chen Y
J Ovarian Res; 2021 Aug; 14(1):108. PubMed ID: 34425872
[TBL] [Abstract] [Full Text] [Related]
12. H3K27ac-induced lncRNA PAXIP1-AS1 promotes cell proliferation, migration, EMT and apoptosis in ovarian cancer by targeting miR-6744-5p/Pcbp2 axis.
Ma Y; Zheng W
J Ovarian Res; 2021 Jun; 14(1):76. PubMed ID: 34108034
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of the short-term efficacy and serum markers between lobaplatin/paclitaxel- And carboplatin/paclitaxel-based adjuvant chemotherapy in patient with ovarian cancer.
Wang W; Liu M; Ding B
J Clin Pharm Ther; 2021 Feb; 46(1):166-172. PubMed ID: 33098169
[TBL] [Abstract] [Full Text] [Related]
14. 1-MT inhibits the invasion of cbp-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function.
Ma H; Qin Q; Mi J; Feng Q
BMC Pharmacol Toxicol; 2020 Sep; 21(1):67. PubMed ID: 32912307
[TBL] [Abstract] [Full Text] [Related]
15. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract] [Full Text] [Related]
16. USP48 Sustains Chemoresistance and Metastasis in ovarian cancer.
Lei X; Li X; Chen H; Liu Z
Curr Cancer Drug Targets; 2020; 20(9):689-699. PubMed ID: 32359336
[TBL] [Abstract] [Full Text] [Related]
17. Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.
Tang D; Zhao YC; Qian D; Liu H; Luo S; Patz EF; Moorman PG; Su L; Shen S; Christiani DC; Glass C; Gao W; Wei Q
Mol Carcinog; 2020 Jan; 59(1):104-115. PubMed ID: 31713888
[TBL] [Abstract] [Full Text] [Related]
18. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF
Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075
[TBL] [Abstract] [Full Text] [Related]
19. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract] [Full Text] [Related]
20. SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells.
Xin L; Zhao R; Lei J; Song J; Yu L; Gao R; Ha C; Ren Y; Liu X; Liu Y; Yao Z; Yang J
FASEB J; 2019 Mar; 33(3):3795-3806. PubMed ID: 30509125
[TBL] [Abstract] [Full Text] [Related]
[Next]
